Drug Profile
Protein C activated - Bioatrix
Alternative Names: aPC - BioatrixLatest Information Update: 19 Nov 2021
Price :
$50
*
At a glance
- Originator University of Sydney
- Developer Bioatrix
- Class Anticoagulants; Antithrombotics; Biological factors; Blood proteins; Enzyme precursors; Glycoproteins
- Mechanism of Action Protein C stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Wounds
Most Recent Events
- 28 Apr 2019 No recent reports of development identified for phase-I development in Wounds in Australia (Topical)